IP-cure-B is a five-year project started in January 2020, coordinated by INSERM in France.
Hepatitis B virus (HBV) is a major global public health threat with over 257 million people worldwide.
Stimulating innate signaling and inhibiting viral replication in infected hepatocytes.
Perform a proof of concept clinical trial to evaluate novel immune modulators and their
combination to boost...
Improve the functional cure rate in « CHB » Chronic Hepatitis B and provide opportunities for finite duration curing